C6 BORRELIOOSITESTI

[Bb]

Lähettäjä: Soijuv Lähetetty: 12.9.2005 9:11

Tutkimuksen mukaan antibioottihoitoja saaneilla C6-taso oli negatiivinen tai aleneminen oli merkittävä. Taso mitattiin sellaisilta henkilöiltä jotka olivat oireettomia 6 - 12 kk antibioottihoitojen jälkeen:


Clin Diagn Lab Immunol. 2005 Sep;12(9):1069-74.

A decline in c6 antibody titer occurs in successfully treated patients with culture-confirmed early localized or early disseminated lyme borreliosis.

Philipp MT, Wormser GP, Marques AR, Bittker S, Martin DS, Nowakowski J, Dally LG.

Department of Bacteriology and Parasitology, Tulane National Primate Research Center, Tulane University Health Sciences Center, 18703 Three Rivers Road, Covington, LA 70433. Philipp@tpc.tulane.edu.

C(6), a Borrelia burgdorferi-derived peptide, is used as the antigen in the C(6)-Lyme disease diagnostic test. We assessed retrospectively whether a fourfold decrease or a decrease to a negative value in anti-C(6) antibody titer is positively correlated with a positive response to treatment in a sample of culture-confirmed patients with either early localized (single erythema migrans [EM]; n = 93) or early disseminated (multiple EM; n = 27) disease. All of these patients had been treated with antibiotics and were free of disease within 6 to 12 months of follow-up. Results show that a serum specimen taken at this time was either C(6) negative or had a 4-fold decrease in C(6) antibody titer with respect to a specimen taken at baseline (or during the early convalescent period if the baseline specimen was C(6) negative) for all of the multiple-EM patients (P < 0.0001) and in 89% of the single-EM patients (P < 0.0001). These results indicate that a decline in anti-C(6) antibody titer coincides with effective antimicrobial therapy in patients with early localized or early disseminated Lyme borreliosis.

PMID: 16148173 [PubMed - in process]
http://www.ncbi.nlm.nih.gov/entrez/quer ... uery_hl=23